Leading expert views on the role of MRD in patient care

The body of evidence supporting MRD assessment in routine patient care is growing. Leading experts share their views on MRD, the evolving role of MRD testing in lymphoid cancers, and insights on how MRD results influence clinical practice decisions.

Dr. Jeffrey Wolf discusses the test performance criteria of an ideal MRD assay and his personal experience using MRD in clinical practice.

Dr. Ola Landgren discusses the prognostic value of MRD and its important role in myeloma due to the deep responses now available.

Dr. Hervé Avet-Loiseau explores prognostic factors in myeloma treatment and the future of MRD.

Dr. Nikil Munshi explains the role of MRD in myeloma treatment and whether MRD negativity should be a considered as a treatment goal.


This article from Nature Research explains, from the perspective of three expert clinicians, how MRD testing can improve personalized treatment plans for patients with lymphoid cancers.

View Arrow

This page is intended for use by healthcare professionals of the United States.

clonoSEQ® is available as a FDA-cleared in vitro diagnostic (IVD) test service provided by Adaptive Biotechnologies to detect minimal residual disease (MRD) in bone marrow from patients with multiple myeloma or B-cell acute lymphoblastic leukemia (B-ALL) and blood or bone marrow from patients with chronic lymphocytic leukemia (CLL). clonoSEQ is also available for use in other lymphoid cancers and specimen types as a CLIA-validated laboratory developed test (LDT). For important information about the FDA-cleared uses of clonoSEQ including test limitations, please visit clonoSEQ.com/technicalsummary.

Test Your clonoSEQ Knowledge

How much do you know about clonoSEQ MRD testing in clinical practice?

clonoSEQ MRD Quiz